Skip to main content

Advertisement

SpringerLink
Log in

An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

An Erratum to this article was published on 14 July 2011

Abstract

We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m2, day 1), ifosfamide (1500 mg/m2 on days 3–7), etoposide (150 mg/m2, days 3–5), cytarabine (100 mg/m2, days 3–5) and dexamethasone (40 mg/body, days 3–5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma. In this study, a total of 32 patients with a median age of 64 years (range 38–79) who received an average of 2.6 cycles of R-IVAD from 2001 to 2009 in our institution were retrospectively analyzed. R-IVAD was given every 3 weeks up to a total of three courses with support by granulocyte colony stimulating factor. The overall response rate was 72%, with 56% complete response. On a median follow-up of 16 months (range 2–99), estimated 2-year overall survival (OS) and event-free survival were 55% and 36%, respectively. Of these patients, 10 successfully proceeded to consolidating high-dose chemotherapy followed by autologous stem cell transplantation, accounting for 90% of the 2-year OS. No treatment-related mortality was observed during the investigation. We, therefore, conclude that R-IVAD regimen is a safe and efficacious alternative for patients with relapsed or refractory aggressive B-cell lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–6.

    Article  PubMed  CAS  Google Scholar 

  2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

    Article  PubMed  CAS  Google Scholar 

  3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.

    Article  PubMed  CAS  Google Scholar 

  4. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.

    Article  PubMed  CAS  Google Scholar 

  5. Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol. 2010;92(2):231–7.

    Article  PubMed  CAS  Google Scholar 

  6. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1993;11(8):1573–82.

    PubMed  CAS  Google Scholar 

  7. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17(12):3776–85.

    PubMed  CAS  Google Scholar 

  8. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–22.

    PubMed  CAS  Google Scholar 

  9. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169–76.

    PubMed  CAS  Google Scholar 

  10. Ogura M, Kagami Y, Taji H, et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol. 2003;77(5):503–11.

    Article  PubMed  CAS  Google Scholar 

  11. Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15(3):511–6.

    Article  PubMed  CAS  Google Scholar 

  12. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–8.

    Article  PubMed  CAS  Google Scholar 

  13. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest. 2006;24(6):593–600.

    Article  PubMed  CAS  Google Scholar 

  14. Harting R, Venugopal P, Gregory SA, O’Brien T, Bogdanova E. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007;7(6):406–12.

    Article  PubMed  CAS  Google Scholar 

  15. Oki Y, Ogura M, Kato H, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Cancer Sci. 2008;99(1):179–84.

    PubMed  CAS  Google Scholar 

  16. Kobayashi S, Yamazaki T, Uenokawa K, et al. New salvage regimen of IVAD therapy for relapsed diffuse large B cell lymphoma. Rinsho Ketsueki. 2005;46(8):793. (in Japanese).

    Google Scholar 

  17. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

  18. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. Project-TIN-HsLPF: a predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.

    Google Scholar 

  19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17(4):1244.

    PubMed  CAS  Google Scholar 

  20. Mey UJ, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006;47(12):2558–66.

    Article  PubMed  CAS  Google Scholar 

  21. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93(12):1829–36.

    Article  PubMed  CAS  Google Scholar 

  22. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.

    Article  PubMed  CAS  Google Scholar 

  23. Niitsu N, Kohuri M, Higashihara M, Bessho M. Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Sci. 2006;97(9):933–7.

    Article  PubMed  CAS  Google Scholar 

  24. Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2011;137(7):1079–84.

    Google Scholar 

  25. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.

    Article  PubMed  Google Scholar 

  26. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006;30(5):625–31.

    Article  PubMed  CAS  Google Scholar 

  27. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561–70.

    Article  PubMed  CAS  Google Scholar 

  28. Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol. 2000;27(6 Suppl 12):30–6.

    PubMed  CAS  Google Scholar 

  29. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005;130(3):363–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medicine, Department of Hematology and Rheumatology, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi Ward, Tokyo, Japan

    Katsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi, Satomi Kiso, Yukio Hirabayashi, Atsuko Hojo, Hitomi Kodaira, Mai Yagi, Daisuke Kurita, Yujin Kobayashi, Toshitake Tanaka, Noriyoshi Iriyama, Yoshihiro Hatta, Yoshimasa Kura, Tetsuo Yamazaki, Umihiko Sawada & Jin Takeuchi

Authors
  1. Katsuhiro Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sumiko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satomi Kiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukio Hirabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsuko Hojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hitomi Kodaira
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mai Yagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daisuke Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yujin Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshitake Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Noriyoshi Iriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshihiro Hatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yoshimasa Kura
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tetsuo Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Umihiko Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jin Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsuhiro Miura.

About this article

Cite this article

Miura, K., Takei, K., Kobayashi, S. et al. An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. Int J Hematol 94, 90–96 (2011). https://doi.org/10.1007/s12185-011-0884-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-011-0884-x

Keywords

Search

Navigation